DK1261602T3 - Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer - Google Patents

Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer

Info

Publication number
DK1261602T3
DK1261602T3 DK01907980T DK01907980T DK1261602T3 DK 1261602 T3 DK1261602 T3 DK 1261602T3 DK 01907980 T DK01907980 T DK 01907980T DK 01907980 T DK01907980 T DK 01907980T DK 1261602 T3 DK1261602 T3 DK 1261602T3
Authority
DK
Denmark
Prior art keywords
sub
sup
alkyl
hydrogen
optionally substituted
Prior art date
Application number
DK01907980T
Other languages
English (en)
Inventor
Alessandra Gaiba
Andrew Kenneth Takle
David Matthew Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DK1261602T3 publication Critical patent/DK1261602T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK01907980T 2000-03-06 2001-03-02 Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer DK1261602T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0005357.9A GB0005357D0 (en) 2000-03-06 2000-03-06 Compounds
PCT/GB2001/000916 WO2001066540A1 (en) 2000-03-06 2001-03-02 Imidazol-2-carboxamide derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1261602T3 true DK1261602T3 (da) 2004-08-30

Family

ID=9887051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01907980T DK1261602T3 (da) 2000-03-06 2001-03-02 Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer

Country Status (12)

Country Link
US (1) US6987119B2 (da)
EP (1) EP1261602B1 (da)
JP (1) JP2003525937A (da)
AT (1) ATE266021T1 (da)
AU (1) AU2001235844A1 (da)
DE (1) DE60103133T2 (da)
DK (1) DK1261602T3 (da)
ES (1) ES2217118T3 (da)
GB (1) GB0005357D0 (da)
PT (1) PT1261602E (da)
TR (1) TR200401903T4 (da)
WO (1) WO2001066540A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
AU1529901A (en) * 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
EP1263753B1 (en) * 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121494D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
JP2005504793A (ja) * 2001-09-05 2005-02-17 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのヘテロサイクルカルボキサミド誘導体
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
AU2003262911A1 (en) 2002-08-29 2004-03-19 Scios Inc. Methods of promoting osteogenesis
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US20050282909A1 (en) * 2003-11-14 2005-12-22 Diks Sander H Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
MX2007002434A (es) * 2004-08-31 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
WO2006024836A1 (en) * 2004-09-01 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
JP2009511628A (ja) * 2005-10-18 2009-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｌｔ３キナーゼの阻害方法
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JP5331681B2 (ja) * 2006-04-20 2013-10-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
KR20130040258A (ko) * 2008-03-21 2013-04-23 노파르티스 아게 신규한 헤테로시클릭 화합물 및 그의 용도
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR20140011780A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1175431A (en) 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
JPH11507669A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EP0854870B1 (en) 1995-10-06 2009-06-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
AU708883B2 (en) 1996-06-10 1999-08-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
DE69729946T2 (de) 1996-10-15 2005-01-20 G.D. Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
IL133766A0 (en) 1997-06-30 2001-04-30 Ortho Mcneil Pharm Inc 2-substituted imidazoles useful in the treatment of inflammatory diseases
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
TR200002616T2 (tr) 1997-12-22 2000-11-21 Bayer Corporation Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
CA2332402A1 (en) 1998-05-22 1999-12-02 Susan B. Dillon Novel 2-alkyl substituted imidazole compounds
AU1529901A (en) 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
ES2289004T3 (es) 2000-11-20 2008-02-01 Smithkline Beecham Corporation Nuevos compuestos.

Also Published As

Publication number Publication date
AU2001235844A1 (en) 2001-09-17
WO2001066540A1 (en) 2001-09-13
JP2003525937A (ja) 2003-09-02
ATE266021T1 (de) 2004-05-15
EP1261602A1 (en) 2002-12-04
ES2217118T3 (es) 2004-11-01
US6987119B2 (en) 2006-01-17
GB0005357D0 (en) 2000-04-26
TR200401903T4 (tr) 2004-09-21
EP1261602B1 (en) 2004-05-06
US20030134837A1 (en) 2003-07-17
DE60103133D1 (de) 2004-06-09
DE60103133T2 (de) 2004-10-14
PT1261602E (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
DK1261602T3 (da) Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
ATE556058T1 (de) 1-(2h)-isochinolonderivat
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
NO20023218D0 (no) 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer
SE0202463D0 (sv) Novel compounds
NO20082101L (no) Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer
TNSN03110A1 (en) Azaindoles.
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
RU2007110629A (ru) Ингибиторы днк-пк
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
EA200601235A1 (ru) Производные тиазола
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
SE0400284D0 (sv) Novel compounds
EA200701780A1 (ru) Противоопухолевое средство
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
DK1320526T3 (da) Farmaceutisk aktive benzsulfonamidderivater som inhibitorer af protein-junkinaser
IS2282B (is) Ný lyfefnasambönd með alfa2viðtakavirkni
DK1899331T3 (da) Homomorpholinoxazolidnoner som antibakterielle midler
EA200001009A1 (ru) Производные пиридина, ингибирующие фосфодиэстеразу iv
RS54061B1 (en) QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONCERNING THEM, AND THEIR APPLICATIONS
SE0301371D0 (sv) New Compounds